The statistical results indicated no significant difference between the groups of patients who received different therapies in T2DM duration, body mass index (BMI), age, fasting blood glucose, HbA1c, LDH, and HOMA-IR score and levels of insulin Ab, C-peptide, uric acid, ketone, Cr, and ALT (Table 1). This evidence concerns the gene GPT and type 2 diabetes mellitus.